In an inflammatory bowel disease (IBD) model, where the accumulation of senescent cells leads to the release of SASP factors that propagate inflammation, fisetin treatment inhibits expressions of p53, p16, Bcl2, Cxcl1, Mcp1, and miRNAs related to senescence and inflammation. This evidence concerns the gene CDKN2A and inflammatory bowel disease.